home / stock / pmn:cc / pmn:cc news

PMN:CC News and Press, Promis Neurosciences Inc. From 04/10/23

Stock Information
Company Name: Promis Neurosciences Inc.
Stock Symbol: PMN:CC
Market: TSXC
Website: promisneurosciences.com
Menu
PMN:CC PMN:CC Quote PMN:CC Short PMN:CC News PMN:CC Articles PMN:CC Message Board
Get PMN:CC Alerts

News, Short Squeeze, Breakout and More Instantly...
PMN:CC - ProMIS Neurosciences Announces Submission of Investigational New Drug (IND) Application for Lead Antibody PMN310

TORONTO, Ontario and CAMBRIDGE, Massachusetts, April 10, 2023 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (TSX: PMN) (Nasdaq: PMN), a biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as...
PMN:CC - Lead Therapeutic Candidate, PMN310, Demonstrates Enhanced Selectivity for Toxic Oligomers Compared to Other Amyloid-Beta-Directed Antibodies in Poster Presentation at AD/PD 2023

TORONTO, Ontario and CAMBRIDGE, Massachusetts, March 29, 2023 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (TSX: PMN) (Nasdaq: PMN), a biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as...

PMN:CC - ProMIS Neurosciences Announces Abstracts Accepted for Presentation at the American Academy of Neurology 2023 Annual Meeting

TORONTO, Ontario and CAMBRIDGE, Massachusetts, March 13, 2023 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (TSX: PMN) (Nasdaq: PMN), a biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as...

PMN:CC - ProMIS Neurosciences to Present New Preclinical Data for PMN310 at AD/PD 2023

TORONTO, Ontario and CAMBRIDGE, Massachusetts, March 13, 2023 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (TSX: PMN) (Nasdaq: PMN), a biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as...
PMN:CC - ProMIS Neurosciences Announces Full Year 2022 Financial Results and Recent Highlights

TORONTO, Ontario and CAMBRIDGE, Massachusetts, March 08, 2023 (GLOBE NEWSWIRE) -- Completed all preclinical studies and manufacturing to support PMN310 IND submission to U.S. Food and Drug Administration Preclinical data that further characterize ongoing programs, including PMN310, to b...

PMN:CC - Promis Neurosciences to Present at the Oppenheimer 33rd Annual Healthcare Conference

TORONTO, Ontario and CAMBRIDGE, Massachusetts, March 08, 2023 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (TSX: PMN) (Nasdaq: PMN), a biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as...

PMN:CC - ProMIS Neurosciences Announces Third Quarter 2022 Financial Results and Recent Highlights

Closed US$7.4 million private placement Appointed Gail Farfel, Ph.D., as Chief Executive Officer Continued progress toward investigational new drug (IND) submission for PMN310 to pursue Alzheimer’s disease indication TORONTO, Ontario and CAMBRIDGE, Massachusetts, ...
PMN:CC - ProMIS Neurosciences Announces Closing of US $7.4 Million Private Placement

Toronto, Ontario and Cambridge, MA, Oct. 12, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN) (TSX: PMN), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic misfolded proteins implicated in the development of neurodegene...

PMN:CC - ProMIS Neurosciences appoints accomplished biopharmaceutical leader, Dr. Gail M. Farfel, as Chief Executive Officer

TORONTO, Ontario and CAMBRIDGE, Massachusetts , Sept. 13, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (Nasdaq: PMN) (TSX: PMN), a biotechnology company focused on the discovery and development of antibody therapeutics targeting misfolded proteins such as toxic oligomers, implica...

PMN:CC - ProMIS Neurosciences Announces Second Quarter 2022 Financial and Operating Results

TORONTO, Ontario and CAMBRIDGE, Massachusetts, Aug. 15, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (Nasdaq: PMN) (“ProMIS” or the “Company”), a biotechnology company focused on the discovery and development of antibody therapeutics targeting m...
Previous 10 Next 10